{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:27:52Z","timestamp":1793392072050,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241229"],"award-info":[{"award-number":["82241229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505000"],"award-info":[{"award-number":["2022YFC2505000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005149","name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["M-202402"],"award-info":[{"award-number":["M-202402"]}],"id":[{"id":"10.13039\/501100005149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pccm.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:48:23Z","timestamp":1757778503000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study"],"prefix":"10.1016","volume":"3","author":[{"given":"Kailun","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-4956","authenticated-orcid":false,"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pccm.2025.08.004_bib0001","first-page":"539","article-title":"Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition) (in Chinese)","volume":"45","year":"2023","journal-title":"Natl Med J China"},{"key":"10.1016\/j.pccm.2025.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.pccm.2025.08.004_bib0003","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review (CSR). Bethesda: National Cancer Institute;2021:1975\u20132018. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2018\/ [Accessed on 9 April 2024]."},{"key":"10.1016\/j.pccm.2025.08.004_bib0004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pccm.2025.08.004_bib0005","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.pccm.2025.08.004_bib0006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00002018-200326100-00003","article-title":"Drug-induced myelosuppression: Diagnosis and management","volume":"26","author":"Carey","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.pccm.2025.08.004_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJCTM.S187569","article-title":"Chemotherapy-induced anemia: Etiology, pathophysiology, and implications for contemporary practice (in Chinese)","volume":"6","author":"Bryer","year":"2018","journal-title":"Int J Clin Transfus Med"},{"key":"10.1016\/j.pccm.2025.08.004_bib0008","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1758834014534515","article-title":"Transfusions and patient burden in chemotherapy-induced anaemia in France","volume":"6","author":"Corey-Lisle","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pccm.2025.08.004_bib0009","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.2217\/fon-2022-0754","article-title":"Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings","volume":"18","author":"Goldschmidt","year":"2022","journal-title":"Future Oncol"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2025.08.004_bib0010","doi-asserted-by":"crossref","first-page":"e19300","DOI":"10.1200\/JCO.2020.38.15_suppl.e19300","article-title":"Real-world burden of myelosuppression in patients with small cell lung cancer (SCLC): Retrospective, longitudinal data analysis","volume":"38","author":"Epstein","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2025.08.004_bib0011","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/13696998.2021.2020570","article-title":"Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: A retrospective analysis of electronic medical data from community cancer care providers","volume":"25","author":"Epstein","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.pccm.2025.08.004_bib0012","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.pccm.2025.08.004_bib0013","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2025.08.004_bib0014","first-page":"86","article-title":"Chinese Anti-Cancer Association; Committee of Neoplastic Supportive-care (CONS), China Anti-Cancer Association. Consensus on the clinical diagnosis, treatment of and prevention chemotherapy-induced neutropenia (2019 edition) (in Chinese)","volume":"11","author":"The Society of Chemotherapy","year":"2019","journal-title":"Chin J Front Sci"},{"key":"10.1016\/j.pccm.2025.08.004_bib0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/1759-7714.14811","article-title":"Efficacy and safety of carboplatin and etoposide in older extensive-stage small-cell lung cancer patients with a poor performance status","volume":"14","author":"Mamesaya","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.pccm.2025.08.004_bib0016","doi-asserted-by":"crossref","first-page":"10020","DOI":"10.1002\/cam4.5738","article-title":"Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices","volume":"12","author":"Hart","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.pccm.2025.08.004_bib0017","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/03007995.2018.1558851","article-title":"Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: A longitudinal assessment","volume":"35","author":"Weycker","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pccm.2025.08.004_bib0018","first-page":"3131","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: A systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Wang","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pccm.2025.08.004_bib0019","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pccm.2023.08.006","article-title":"Changing profile of lung cancer clinical characteristics in China: Over 8-year population-based study","volume":"1","author":"Xu","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"10.1016\/j.pccm.2025.08.004_bib0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2025.08.004_bib0021","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.pccm.2025.08.004_bib0022","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pccm.2025.08.004_bib0023","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"Pt 2","key":"10.1016\/j.pccm.2025.08.004_bib0024","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: A descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31","author":"Wu","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.pccm.2025.08.004_bib0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00044011-200727060-00002","article-title":"Economic burden of haematological adverse effects in cancer patients: a systematic review","volume":"27","author":"Liou","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pccm.2025.08.004_bib0026","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","article-title":"Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012","volume":"13","author":"Tai","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.pccm.2025.08.004_bib0027","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"Wong","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pccm.2025.08.004_bib0028","first-page":"657","article-title":"Pharmacoeconomic research on adverse drug reactions of chemotherapy for lung cancer (in Chinese)","volume":"32","author":"Wang","year":"2012","journal-title":"J Shanghai Jiaotong Univ (Med Sci)"},{"key":"10.1016\/j.pccm.2025.08.004_bib0029","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1200\/JCO.2005.02.7110","article-title":"Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: A review","volume":"24","author":"Yang","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2025.08.004_bib0030","unstructured":"Sp\u00e1sov\u00e1 I. Treatment of the unresectable non small cell lung carcinoma. Cas Lek Cesk. 2005;144:602\u2013612; discussion 612\u2013613."},{"key":"10.1016\/j.pccm.2025.08.004_bib0031","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.pccm.2025.08.004_bib0032","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","article-title":"NCCN Guidelines\u00ae Insights: Hematopoietic Growth Factors, Version 1.2022","volume":"20","author":"Griffiths","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.pccm.2025.08.004_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.697908","article-title":"Improving outcomes of chemotherapy: Established and novel options for myeloprotection in the COVID-19 era","volume":"11","author":"Lyman","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.pccm.2025.08.004_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107455","article-title":"Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)","volume":"188","author":"Cheng","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pccm.2025.08.004_bib0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","article-title":"Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: Pooled results from three phase II randomized, double-blind, placebo-controlled studies","volume":"22","author":"Weiss","year":"2021","journal-title":"Clin Lung Cancer"}],"container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558825000507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558825000507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:32:35Z","timestamp":1775100755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772558825000507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2772558825000507"],"URL":"https:\/\/doi.org\/10.1016\/j.pccm.2025.08.004","relation":{},"ISSN":["2772-5588"],"issn-type":[{"value":"2772-5588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study","name":"articletitle","label":"Article Title"},{"value":"Chinese Medical Journal Pulmonary and Critical Care Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pccm.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association.","name":"copyright","label":"Copyright"}]}}